VANCOUVER, July 2 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that data from a study evaluating its Periowave Photodynamic Disinfection System will be presented at the International Association for Dental Research (IADR) 86th General Session & Exhibition in Toronto, Ontario on Thursday, July 3, 2008.

A poster presentation, entitled, "In vitro Bactericidal Efficacy of Periowave Photodynamic Disinfection System", based on research conducted by Loma Linda University School of Dentistry (Loma Linda, California), will be presented on Thursday, July 3, 2008 from 3:30 pm to 4:45 pm (Metro Toronto Convention Centre Exhibit Hall D-E, abstract 1281).

"Periowave(TM) was used in this study to eradicate Gram-negative bacteria including E. faecalis, which can be difficult to kill even using bleach disinfection," stated Dr. Nicolas Loebel, Ondine's Chief Technology Officer. "The bacteria are unaffected by the light or the photosensitizer when used alone. When exposed to the Periowave(TM) Photodisinfection System, these virulent pathogens are completely eliminated within 60 seconds. Because Periowave(TM) works so differently to antibiotics, it does not increase bacterial resistance - an important advantage as more and more bacteria develop immunity to the conventional agents used today. Periowave(TM) provides the practitioner with a non-antibiotic alternative that has been proven safe and effective in clinical practice, eradicating bacteria associated with many different disease processes."

Further details on the abstract are available at:

http://iadr.confex.com/iadr/2008Toro...

About Periowave(TM)

Periowave(TM) is a photodisinfection system commercialized by Ondine that utilizes low-intensity lasers and microbiological stains to target and destroy microbial pathogens and reduce the symptoms of disease. The photodisinfection technology was developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business plc, University College London. Periowave(TM) is currently approved in Canada and the European Union for several oral indications. Additional information about Periowave(TM) is available at www.periowave.com

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com